Rigel Pharma Tops Q2 EPS by 4c

  • Investing.com
Rigel Pharma Tops Q2 EPS by 4c

Rigel Pharma (NASDAQ: RIGL ) reported Q2 EPS of ($0.08), $0.04 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $23.82 million.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles